Largest Long-Term Study Confirms EDAP's AblathermŪ HIFU is Effective, Highly Reproducible Primary Treatment for Localized Prostate Cancer

Tuesday, May 17, 2011 General News
Email Print This Page Comment
Font : A-A+

-- 2,552 Patient, International, Multi-Center, 10-year Study Shows 83% of Patients Cancer Free --

Company Contact:

Blandine ConfortInvestor Relations / Legal Affairs+33 4 72 15 31 72bconfort@edap-tms.com

Media/Investors:

Kim Muscara/Stephanie Carrington  646-536-7011/7017 kmuscara@theruthgroup.com scarrington@theruthgroup.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook